title: Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats.
abstract: The possible effect of a cholecystokinin-8 agonist (caerulein) and antagonists (MK-329 and L365,260) on the development of morphine dependence and withdrawal were investigated in rats. Caerulein treatment (0.01 and 0.1 mg/kg) increased the incidence of naloxone-induced withdrawal syndromes and delayed the extinction of morphine-conditioned place preference in morphine-dependent animals. The signs of the morphine withdrawal syndromes and the formation of morphine-conditioned place preference were suppressed by pretreatment with L365,260 (0.1 and 1 mg/kg) and not affected by pretreatment with MK-329 (0.1 and 1 mg/kg). The present study demonstrated CCK, acting on CCK-B receptors, participates in the development of the opiate dependence. These findings suggest that CCK-B receptor antagonists might be of some value in the treatment and prevention the relapse of opiate addicts.
authors.affiliation: Institute of Mental Health, West China University of Medical Sciences, Chengdu, People's Republic of China.
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: M
authors.initials: M
authors.lastname: Huang
authors.forename: Z
authors.initials: Z
authors.lastname: Liu
authors.forename: L
authors.initials: L
authors.lastname: Ma
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D002108:Ceruletide / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D020109:Devazepide / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D009021:Morphine Dependence / Q000188:drug therapy* / Q000503:physiopathology*; D010671:Phenylurea Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000187:drug effects*; D012844:Sincalide / Q000819:agonists / Q000037:antagonists & inhibitors; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D010671:Phenylurea Compounds; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C058121:L 365260; D002108:Ceruletide; D020109:Devazepide; D012844:Sincalide